These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24351423)

  • 1. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.
    Booth L; Roberts JL; Conley A; Cruickshanks N; Ridder T; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 Mar; 15(3):305-16. PubMed ID: 24351423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
    Tang Y; Yacoub A; Hamed HA; Poklepovic A; Tye G; Grant S; Dent P
    Cancer Biol Ther; 2012 May; 13(7):567-74. PubMed ID: 22406992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
    BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
    Asklund T; Kvarnbrink S; Holmlund C; Wibom C; Bergenheim T; Henriksson R; Hedman H
    Anticancer Res; 2012 Jul; 32(7):2407-13. PubMed ID: 22753697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
    Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
    Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
    Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA; Yamaguchi Y; Fisher PB; Grant S; Dent P
    J Cell Physiol; 2013 Oct; 228(10):1996-2005. PubMed ID: 23674352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
    Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
    Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
    Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
    Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate augments Niraparib killing of tumor cells.
    Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
    Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
    Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
    Park MA; Zhang G; Martin AP; Hamed H; Mitchell C; Hylemon PB; Graf M; Rahmani M; Ryan K; Liu X; Spiegel S; Norris J; Fisher PB; Grant S; Dent P
    Cancer Biol Ther; 2008 Oct; 7(10):1648-62. PubMed ID: 18787411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
    Thomas S; Thurn KT; Biçaku E; Marchion DC; Münster PN
    Breast Cancer Res Treat; 2011 Nov; 130(2):437-47. PubMed ID: 21298336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
    Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
    J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
    Walker T; Mitchell C; Park MA; Yacoub A; Graf M; Rahmani M; Houghton PJ; Voelkel-Johnson C; Grant S; Dent P
    Mol Pharmacol; 2009 Aug; 76(2):342-55. PubMed ID: 19483104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
    Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
    Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.